Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Xintela AB is a biotechnology company focused on the development of regenerative medicine and cancer treatments. The company's primary function revolves around its proprietary technology platform, XINMARK, which utilizes specific integrin markers to select and characterize cells for therapeutic purposes. This innovative approach is central in the company's efforts to develop advanced cell therapy products aimed at treating cartilage damage and cancer. Notably, Xintela operates within the healthcare sector, impacting industries focused on orthopedics and oncology. Its work in cartilage repair is significant for conditions like osteoarthritis, which affects millions globally, and places Xintela at the forefront of addressing unmet medical needs. Additionally, the company's exploration into targeted cancer therapies highlights its commitment to pioneering innovative solutions in the biopharmaceutical landscape. With its cutting-edge research and development, Xintela AB plays a crucial role in advancing medical treatment capabilities. Headquartered in Lund, Sweden, the company continues to leverage its scientific expertise to introduce potentially transformative therapies, marking its significance within the global biotech industry.
kr 0.01
+kr 0.00 (+25.00%)
Live · 10:02 PM · Twelve Data
The business is unprofitable at the operating level (-2045.75% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 45.9% YoY. Margins deteriorated 1109.9pp alongside, both lines moving the wrong way.
Negative free cash flow of -kr 42M. The business is consuming cash, not generating it. Operating margin contracted 1109.9pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 3M
▼ -45.9% YoY
Net Income (TTM)
-kr 50M
▼ -23.9% YoY
Op. Margin
-1848.94%
▼ -1109.9pp YoY
ROIC
-368.80%
▲ +1054.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 44M
▼ -2.2% YoY
Op. Cash Flow (TTM)
-kr 42M
▼ -0.2% YoY
Net Debt
-kr 3M
Net Cash Position
Cash & Equiv.
kr 23M
Continue Research
Xintela AB (XINT.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Xintela AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Xintela AB scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,848.9% operating margin and a -368.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh XINT.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.